Blockchain Registration Transaction Record

Kairos Pharma Wins 2025 Award for Prostate Cancer Drug Breakthrough

Kairos Pharma wins 2025 Clinical Trials Arena Award for ENV-105, a CD105-targeting drug showing promise in resistant prostate cancer trials. Read about the breakthrough.

This development matters because metastatic castration-resistant prostate cancer (mCRPC) is a lethal and treatment-resistant form of cancer with limited effective options, leading to poor patient outcomes. A therapy like ENV-105, which targets the specific biological mechanism of drug resistance (CD105), represents a paradigm shift in oncology. If successful, it could not only extend survival and improve quality of life for prostate cancer patients but also validate a new approach to overcoming treatment resistance that could be applied to other cancers like lung cancer, where Kairos is also testing the drug. For the biopharmaceutical industry and investors, it signals progress in a high-need therapeutic area and highlights the value of innovative R&D targeting fundamental cancer biology. For patients and families, it offers tangible hope for a more effective treatment strategy in the near future.